Bayer HealthCare announced today that its affiliate, MEDRAD, Inc. has acquired Pathway Medical Technologies, Inc., of Kirkland, Wash. Financial terms of the agreement were not disclosed. With this acquisition, Bayer HealthCare is strengthening its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the start of a synergistic initiative to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania as part of their global social contribution activities.

At an award ceremony in Paris, the 32 winning projects of the global disease awareness initiative 1 Mission 1 Million - Getting to the Heart of Stroke were announced. The projects were chosen by the public and a panel of experts.

AstraZeneca today announced results from a blinded review of clinical data from patients in the PLATO trial who had died following coronary artery bypass graft (CABG) surgery.

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

Novo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark. The project is expected to create more than 300 jobs during the construction phase.